Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-115 in p53 Wild-type Salivary Gland Carcinoma
NCT03781986Phase 2Active, not recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2019
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alrizomadlin in salivary gland cancer (SGC), sponsored by University of Michigan Rogel Cancer Center. Started Oct 2019; status: active, not recruiting.
02
Drugs
alrizomadlin
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT03781986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781986.